Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)

NCT00682383 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Locally Advanced NSCLC

Interventions

DRUG: Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta

Sponsor

Mt. Sinai Medical Center, Miami

Collaborators

[object Object]